Could a DSIP receptor still be found?

Possible. Receptors have been identified decades after their ligands. But sustained failure across nearly fifty years is itself informative.

Does no gene mean DSIP is not endogenous?

It means it has not been established as endogenous. That is a weaker statement than refutation, and a much weaker one than the name implies.

How does this compare with other research peptides?

MOTS-c and humanin both have identified coding sequences in the mitochondrial genome. DSIP has none in any genome, which is the clearest contrast available.

DSIP (Delta Sleep-Inducing Peptide)

The Missing Biology: No Gene, No Precursor, No Receptor

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

No DSIP gene has been isolated, no precursor protein identified and no receptor characterised. Those three findings are how a proposed endogenous peptide normally becomes accepted biology, and DSIP has none of them nearly fifty years after isolation.

Key facts

Gene: Not identified
Precursor protein: Not characterised
Receptor: Not identified
Time since isolation: Nearly 50 years
Consequence: No mechanism to test; no knockout possible
Contrast: MOTS-c, humanin — both gene-located

How an endogenous peptide normally gets established

There is a recognisable sequence. A peptide is isolated and sequenced. Its gene is located, which explains where it comes from and how its production is regulated. A precursor protein is characterised, showing how it is processed. A receptor is identified, giving a mechanism and a target. At that point the peptide has a place in physiology rather than a suggestive result attached to it.

What DSIP has and has not

It has an isolation, a sequence, a synthesis and a large literature. It does not have a gene, a precursor or a receptor. Each absence is individually surmountable — plenty of molecules waited decades for a receptor — but the combination, sustained across nearly fifty years of active interest, is unusual and is the single most informative fact about the compound.

Research material referenced

DSIP 5mg — third-party HPLC tested

View — £13.99

Why a missing receptor is the hardest gap

A receptor is what makes a mechanism testable. With one, you can measure binding, build dose-response relationships, design antagonists and establish whether an observed effect actually runs through the proposed pathway. Without one, an observed effect can only be described, not explained, and cannot be distinguished from action through some entirely different route.

Why a missing gene is the hardest to explain

Modern genomics is very good at finding coding sequences. MOTS-c was located inside the mitochondrial 12S rRNA gene in 2015 — a short open reading frame nested inside sequence already annotated as something else, and it was still found. That a putative endogenous peptide first described in 1977 has no identified gene in the genomic era is a substantive observation about its likely status.

What this does not prove

Absence of evidence is not proof of absence. It remains possible that DSIP has an endogenous role yet to be characterised. The honest position is not that DSIP has been refuted but that it has never been established, and that the specific gaps are the ones that would matter most.

How to weigh it against the published literature

When a study reports an effect of administered DSIP, that effect is being produced by a synthetic peptide at an experimentally chosen concentration through an unknown mechanism. That can still be a real and interesting observation. It is not evidence that the compound performs a physiological function, and the two claims should not be reported as one.

Extended research context

The DSIP (Delta Sleep-Inducing Peptide) deep dive

Deep dive: a name that was a hypothesis, not a finding

In 1977 the Schoenenberger-Monnier group in Basel electrically stimulated the thalamus of a sleeping rabbit, collected blood draining from its brain, isolated a peptide fraction, and reported that administering it into the ventricles of awake rabbits produced delta-wave EEG activity. They named it delta sleep-inducing peptide. By the standards of the time this was careful, imaginative work, and they followed it properly - the 1978 Pflugers Archiv paper reported sequence, synthesis and activity of the synthetic nonapeptide rather than stopping at a suggestive fraction. The problem is not the original research. It is that a name recording a hypothesis has been read ever since as a summary of established pharmacology, and almost nobody checks whether it was earned.

Deep dive: the three things that are missing

A proposed endogenous peptide becomes accepted biology by a recognisable route. The gene is located. The precursor protein is characterised. A receptor is identified, giving a mechanism and a testable target. DSIP has completed none of these in nearly fifty years. The receptor gap is the most disabling - without one there is no mechanism to test, no dose-response to build, no antagonist to design, and no way to establish that an observed effect runs through the proposed pathway at all. The gene gap is the hardest to explain away: modern genomics located MOTS-c inside a short open reading frame nested within the mitochondrial 12S rRNA gene, sequence already annotated as something else. That a peptide described in 1977 still has no identified gene in any genome is a substantive observation, not an accident of effort.

Deep dive: why 519 papers is not 519 confirmations

DSIP has roughly 519 indexed PubMed records - more than Selank's 135 or Semax's 231. Publication volume tracks how interesting a question is, not how well it has been answered. A tractable question generates a burst of work and then stops; a question that resists resolution generates papers indefinitely, each a further attempt rather than a further confirmation. Kovalzon's 2006 review in the Journal of Neurochemistry states the field's own assessment in its title: a still unresolved riddle. Reading any individual DSIP paper without that context invites mistaking activity for consensus.

Research applications

▸Historical study of humoral sleep-factor hypotheses
▸Electroencephalography and delta-wave research methodology
▸Structure-activity work on flexible, acidic short peptides
▸Comparative work on peptides lacking identified receptors
▸Analytical method development for tryptophan-containing peptides

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓No reducing agent needed — the sequence contains no cysteine
✓No methionine oxidation to expect; a +16 Da satellite warrants explanation
✓Protect from prolonged light — the single tryptophan is mildly photosensitive
✓Expect pH-dependent solubility; the peptide is strongly acidic with no basic residue
✓Aliquot to avoid repeated freeze-thaw cycles

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating the name as evidence of the effect

Fix: The name records a 1977 hypothesis from a single rabbit EEG study. It is not a summary of established pharmacology.

✗ Citing the 1977 paper as proof DSIP induces sleep

Fix: It reports delta-wave EEG activity in rabbits after intraventricular administration — a narrower claim than inducing sleep, in one species, by a route that bypasses every normal barrier.

✗ Assuming DSIP is an established endogenous human peptide

Fix: No gene has been identified in any species, no precursor characterised and no receptor found.

✗ Reading 519 papers as 519 confirmations

Fix: Volume reflects an unresolved question attracting sustained attempts, not accumulated confirmation.

✗ Making any sleep claim about supplied material

Fix: The evidence does not support it and a therapeutic claim about research material is what MHRA enforcement targets.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Could a DSIP receptor still be found?: Possible. Receptors have been identified decades after their ligands. But sustained failure across nearly fifty years is itself informative.
Does no gene mean DSIP is not endogenous?: It means it has not been established as endogenous. That is a weaker statement than refutation, and a much weaker one than the name implies.
How does this compare with other research peptides?: MOTS-c and humanin both have identified coding sequences in the mitochondrial genome. DSIP has none in any genome, which is the clearest contrast available.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More DSIP (Delta Sleep-Inducing Peptide) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum